JONESBORO, Ark.–(BUSINESS WIRE)–SylamoreBio, a biotechnology company pioneering advanced therapeutic delivery to the central nervous system (CNS) and other recalcitrant tissues, today announced it has entered into a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego. The collaboration will leverage SylamoreBio’s proprietary SyLEC delivery technology in tandem with the world-class drug discovery and development expertise of Daiichi Sa
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
